Ipragliflozin (L-Proline) is a highly potent and selectiveSGLT2inhibitor with anIC₅₀of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

IC50 value: 2.8 nM (SGLT2)^[1][2].

Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases^[3].

Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice^[3]. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h^[4]. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance^[5].

519.58

C₂₆H₃₀FNO₇S

951382-34-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.